Use access key #2 to skip to page content.
$66.89 1.93 (2.97%)
10/6/2008 4:00 PM

ImClone Systems, Inc. (IMCL)

CAPS Rating:
**

A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

View All Commentary (IMCL)

Recs

0

Avatar prosper21 (< 20) Submitted: 1/06/08 1:25 PM : Outperform Start Price: $40.64 IMCL Score: 90.75

Up coming presentation of Phase 3 data from Flex Study around June 2008 ASCO conference should
make this stocks a great speculative buy.

not to mention a great pipeline and great chance of a buy out.

Report this Post Replies: 0 | Reply

Featured Broker Partners